|

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

RECRUITINGN/ASponsored by Zealand University Hospital
Actively Recruiting
PhaseN/A
SponsorZealand University Hospital
Started2023-07-28
Est. completion2027-06
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05889247

Summary

The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)
* Advanced or locally advanced disease without curative intended treatment options
* Age \> 18 years
* Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1
* Measurable disease according to the iRECIST criteria version 1.1.
* Eligible to first line immunotherapy (monotherapy)
* Signed informed consent

Exclusion Criteria:

* Targetable alterations in EGFR, ALK or ROS-1
* Other active cancers

Conditions3

CancerLung CancerNon-small Cell Lung Cancer Metastatic

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.